Which of the following is the first FDA-approved intravenous (IV) treatment for migraine prevention?
a. Imitrex
b. Relpax
c. Zomig
d. Cambia
e. Vyepti
Answer: (e).
The active ingredient found in Vyepti is Eptinezumab-jjmr. It is the first FDA-approved intravenous (IV) treatment for migraine prevention.
Vyepti (Eptinezumab-jjmr) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
The recommended dose is 100 mg every 3 months; some patients may benefit from a dose of 300 mg.
Ready for the full prep?
Continue your preparation with full NAPLEX practice questions, question bank access, and study materials.
Go to NAPLEX Study Materials